KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Current Leases (2017 - 2025)

Astrazeneca has reported Current Leases over the past 8 years, most recently at $382.0 million for Q4 2025.

  • Quarterly results put Current Leases at $382.0 million for Q4 2025, up 12.68% from a year ago — trailing twelve months through Dec 2025 was $382.0 million (up 12.68% YoY), and the annual figure for FY2025 was $382.0 million, up 12.68%.
  • Current Leases for Q4 2025 was $382.0 million at Astrazeneca, up from $339.0 million in the prior quarter.
  • Over the last five years, Current Leases for AZN hit a ceiling of $382.0 million in Q4 2025 and a floor of $228.0 million in Q4 2022.
  • Median Current Leases over the past 5 years was $271.0 million (2023), compared with a mean of $290.6 million.
  • Biggest five-year swings in Current Leases: fell 2.15% in 2022 and later increased 25.09% in 2024.
  • Astrazeneca's Current Leases stood at $233.0 million in 2021, then fell by 2.15% to $228.0 million in 2022, then rose by 18.86% to $271.0 million in 2023, then increased by 25.09% to $339.0 million in 2024, then grew by 12.68% to $382.0 million in 2025.
  • The last three reported values for Current Leases were $382.0 million (Q4 2025), $339.0 million (Q4 2024), and $271.0 million (Q4 2023) per Business Quant data.